Provenzano Michele, Hu Lilio, Tringali Edoardo, Senatore Massimo, Talarico Roberta, Di Dio Michele, Ruotolo Chiara, La Manna Gaetano, Garofalo Carlo, Zaza Gianluigi
Department of Pharmacy Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Biomedicines. 2024 Apr 9;12(4):828. doi: 10.3390/biomedicines12040828.
Nephrology is an ever-evolving field of medicine. The importance of such a discipline is related to the high clinical impact of kidney disease. In fact, abnormalities of kidney function and/or structure are common in the general population, reaching an overall prevalence of about 10%. More importantly, the onset of kidney damage is related to a strikingly high risk of cardiovascular events, mortality, and progression to kidney failure which, in turn, compromises quality and duration of life. Attempts to comprehend the pathogenesis and molecular mechanisms involved in kidney disease occurrence have prompted the development and implementation of novel drugs in clinical practice with the aim of treating the 'specific cause' of kidney disease (including chronic kidney disease, glomerular disease, and genetic kidney disorders) and the main immunological complications following kidney transplantation. Herein, we provide an overview of the principal emerging drug classes with proved efficacy in the context of the aforementioned clinical conditions. This can represent a simplified guide for clinical nephrologists to remind them of the vast and heterogeneous armamentarium of drugs that should be used in the present and the future to improve the management of patients suffering from kidney disease.
肾脏病学是一个不断发展的医学领域。这样一门学科的重要性与肾脏疾病的高临床影响相关。事实上,肾功能和/或结构异常在普通人群中很常见,总体患病率约为10%。更重要的是,肾损伤的发生与心血管事件、死亡率以及进展为肾衰竭的极高风险相关,而这反过来又会影响生活质量和寿命。为了理解肾脏疾病发生的发病机制和分子机制,人们在临床实践中开发并应用了新型药物,旨在治疗肾脏疾病(包括慢性肾脏病、肾小球疾病和遗传性肾脏疾病)的“特定病因”以及肾移植后的主要免疫并发症。在此,我们概述了在上述临床情况下已证明有效的主要新兴药物类别。这可以为临床肾脏病学家提供一个简化的指南,提醒他们在当前和未来用于改善肾脏病患者管理的广泛且多样的药物库。